Associated Genetic Biomarkers
MAPK3 is altered in 0.77% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in MAPK3 are MAPK3 Mutation (0.42%), MAPK3 Amplification (0.25%), MAPK3 Loss (0.07%), MAPK3 D300E (0.01%), and MAPK3 Fusion (0.04%) .
MAPK3 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain MAPK3 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with MAPK3 status in the inclusion eligibility criteria most commonly target cholangiocarcinoma, colorectal carcinoma, esophageal carcinoma, gastric carcinoma, and malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are MAPK3 Mutation and MAPK3 Fusion .
Abemaciclib, hydroxychloroquine, temuterkib, and ulixertinib are the most frequent therapies in trials with MAPK3 as an inclusion criteria .
Significance of MAPK3 in Diseases
Gastric Carcinoma +
Colorectal Carcinoma +
Malignant Solid Tumor +
Esophageal Carcinoma +
Pancreatic Adenocarcinoma +
MAPK3 is altered in 0.18% of pancreatic adenocarcinoma patients .
MAPK3 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.